Role of cellular L-arginine uptake and nitric oxide production on renal blood flow and arterial pressure regulation

被引:25
作者
Rajapakse, Niwanthi W. [2 ]
Mattson, David L. [1 ]
机构
[1] Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA
[2] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia
关键词
hypertension; kidney; L-Arg transport; nitric oxide; AMINO-ACID TRANSPORTER; SPONTANEOUSLY HYPERTENSIVE-RATS; OXIDATIVE STRESS; ANGIOTENSIN-II; ENDOTHELIAL FUNCTION; VASCULAR-DISEASE; SYNTHASE; SUBSTRATE; INFUSION; DIMETHYLARGININE;
D O I
10.1097/MNH.0b013e32835a6ff7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review L-Arginine (L-Arg) is the substrate for nitric oxide (NO) formation. Reduced NO bioavailability, particularly within the renal circulation, has been identified as a key factor in the pathogenesis of hypertension. This review focuses on the pathogenic role of abnormal L-Arg transport, particularly within the kidney, in hypertension. Recent findings Most recent studies have attempted to restore NO bioavailability in cardiovascular diseases with the use of antioxidants to reduce NO inactivation, but this approach has failed to provide beneficial effects in the clinical setting. We argue that this may be due to reduced NO formation in hypertension, which has largely been overlooked as a means of restoring NO bioavailability in cardiovascular diseases. Recent data indicate that renal L-Arg transport plays an important role in regulating both renal perfusion and function and the long-term set point of arterial pressure in health. Perturbations in the renal L-Arg transport system can give rise to abnormal renal perfusion and function, initiating hypertension and related renal damage. Summary Accordingly, we propose that L-Arg transporters are a new treatment target in hypertension and in disease states where renal NO bioavailability is disturbed.
引用
收藏
页码:45 / 50
页数:6
相关论文
共 48 条
[1]   Molecular sites of regulation of expression of the rat cationic amino acid transporter gene [J].
Aulak, KS ;
Liu, J ;
Wu, JY ;
Hyatt, SL ;
Puppi, M ;
Henning, SJ ;
Hatzoglou, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (47) :29799-29806
[2]   Salt intake determines the renal response to L-arginine infusion in normal human subjects [J].
Barri, YM ;
Wilcox, CS .
KIDNEY INTERNATIONAL, 1998, 53 (05) :1299-1304
[3]   SUBSTRATE-DEPENDENT REGULATION OF INTRACELLULAR AMINO-ACID-CONCENTRATIONS IN CULTURED BOVINE AORTIC ENDOTHELIAL-CELLS [J].
BAYDOUN, AR ;
EMERY, PW ;
PEARSON, JD ;
MANN, GE .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 173 (03) :940-948
[4]   Nitric oxide synthase derangements and hypertension in kidney disease [J].
Baylis, Chris .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2012, 21 (01) :1-6
[5]   Renal arginine metabolism [J].
Brosnan, ME ;
Brosnan, JT .
JOURNAL OF NUTRITION, 2004, 134 (10) :2791S-2795S
[6]   Whole body nitric oxide synthesis in healthy men determined from [N-15]arginine-to-[N-15]citrulline labeling [J].
Castillo, L ;
Beaumier, L ;
Ajami, AM ;
Young, VR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (21) :11460-11465
[7]   L-Arginine transporters in cardiovascular disease: A novel therapeutic target [J].
Chin-Dusting, J. P. F. ;
Willems, L. ;
Kaye, D. M. .
PHARMACOLOGY & THERAPEUTICS, 2007, 116 (03) :428-436
[8]   Arginine: NO more than a simple aminoacid? [J].
Chowienczyk, P ;
Ritter, J .
LANCET, 1997, 350 (9082) :901-902
[9]  
Closs EI, 2000, MOL PHARMACOL, V57, P68
[10]   Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B [J].
Closs, EI ;
Basha, FZ ;
Habermeier, A ;
Forstermann, U .
NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 1997, 1 (01) :65-73